ID   IRAK1_HUMAN             Reviewed;         712 AA.
AC   P51617; Q7Z5V4; Q96RL2;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   02-NOV-2010, entry version 111.
DE   RecName: Full=Interleukin-1 receptor-associated kinase 1;
DE            Short=IRAK-1;
DE            EC=2.7.11.1;
GN   Name=IRAK1; Synonyms=IRAK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE, AND
RP   VARIANTS SER-196 AND LEU-532.
RX   MEDLINE=96180673; PubMed=8599092; DOI=10.1126/science.271.5252.1128;
RA   Cao Z., Henzel W.J., Gao X.;
RT   "IRAK: a kinase associated with the interleukin-1 receptor.";
RL   Science 271:1128-1131(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   MEDLINE=20188769; PubMed=10723722; DOI=10.1007/s003350010035;
RA   Reichwald K., Thiesen J., Wiehe T., Weitzel J., Poustka W.A.,
RA   Rosenthal A., Platzer M., Stratling W.H., Kioschis P.;
RT   "Comparative sequence analysis of the MECP2-locus in human and mouse
RT   reveals new transcribed regions.";
RL   Mamm. Genome 11:182-190(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, TISSUE SPECIFICITY,
RP   AND PHOSPHORYLATION.
RX   MEDLINE=21369999; PubMed=11397809; DOI=10.1074/jbc.M103815200;
RA   Jensen L.E., Whitehead A.S.;
RT   "IRAK1b, a novel alternative splice variant of interleukin-1 receptor-
RT   associated kinase (IRAK), mediates interleukin-1 signaling and has
RT   prolonged stability.";
RL   J. Biol. Chem. 276:29037-29044(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH IRAK4.
RX   MEDLINE=21957277; PubMed=11960013; DOI=10.1073/pnas.082100399;
RA   Li S., Strelow A., Fontana E.J., Wesche H.;
RT   "IRAK4: a novel member of the IRAK family with the properties of an
RT   IRAK-kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:5567-5572(2002).
RN   [6]
RP   INTERACTION WITH PELI1.
RX   MEDLINE=22538429; PubMed=12496252; DOI=10.1074/jbc.M212112200;
RA   Jiang Z., Johnson H.J., Nie H., Qin J., Bird T.A., Li X.;
RT   "Pellino 1 is required for interleukin-1 (IL-1)-mediated signaling
RT   through its interaction with the IL-1 receptor-associated kinase 4
RT   (IRAK4)-IRAK-tumor necrosis factor receptor-associated factor 6
RT   (TRAF6) complex.";
RL   J. Biol. Chem. 278:10952-10956(2003).
RN   [7]
RP   INTERACTION WITH PELI2.
RX   MEDLINE=22744764; PubMed=12860405; DOI=10.1016/S0014-5793(03)00697-5;
RA   Strelow A., Kollewe C., Wesche H.;
RT   "Characterization of Pellino2, a substrate of IRAK1 and IRAK4.";
RL   FEBS Lett. 547:157-161(2003).
RN   [8]
RP   INTERACTION WITH PELI3.
RX   MEDLINE=22756745; PubMed=12874243;
RA   Jensen L.E., Whitehead A.S.;
RT   "Pellino3, a novel member of the Pellino protein family, promotes
RT   activation of c-Jun and Elk-1 and may act as a scaffolding protein.";
RL   J. Immunol. 171:1500-1506(2003).
RN   [9]
RP   FUNCTION, AND MUTAGENESIS OF LYS-239.
RX   PubMed=15084582; DOI=10.1074/jbc.M400785200;
RA   Qin J., Jiang Z., Qian Y., Casanova J.-L., Li X.;
RT   "IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor-
RT   associated kinase phosphorylation and IL-1 responsiveness.";
RL   J. Biol. Chem. 279:26748-26753(2004).
RN   [10]
RP   INTERACTION WITH IL1RL1.
RX   PubMed=16286016; DOI=10.1016/j.immuni.2005.09.015;
RA   Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K.,
RA   Zurawski G., Moshrefi M., Qin J., Li X., Gorman D.M., Bazan J.F.,
RA   Kastelein R.A.;
RT   "IL-33, an interleukin-1-like cytokine that signals via the IL-1
RT   receptor-related protein ST 2 and induces T helper type 2-associated
RT   cytokines.";
RL   Immunity 23:479-490(2005).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-568, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=16094384; DOI=10.1038/nmeth776;
RA   Tao W.A., Wollscheid B., O'Brien R., Eng J.K., Li X.-J.,
RA   Bodenmiller B., Watts J.D., Hood L., Aebersold R.;
RT   "Quantitative phosphoproteome analysis using a dendrimer conjugation
RT   chemistry and tandem mass spectrometry.";
RL   Nat. Methods 2:591-598(2005).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-131 AND SER-371, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   UBIQUITINATION.
RX   PubMed=19675569; DOI=10.1038/nature08247;
RA   Xia Z.-P., Sun L., Chen X., Pineda G., Jiang X., Adhikari A., Zeng W.,
RA   Chen Z.J.;
RT   "Direct activation of protein kinases by unanchored polyubiquitin
RT   chains.";
RL   Nature 461:114-119(2009).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] MET-398; MET-412; HIS-421; LEU-532;
RP   SER-619; MET-625; TRP-638 AND GLY-690.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Binds to the IL-1 type I receptor following IL-1
CC       engagement, triggering intracellular signaling cascades leading to
CC       transcriptional up-regulation and mRNA stabilization. Isoform 1
CC       binds rapidly but is then degraded allowing isoform 2 to mediate a
CC       slower, more sustained response to the cytokine. Isoform 2 is
CC       inactive suggesting that the kinase activity of this enzyme is not
CC       required for IL-1 signaling. Once phosphorylated, IRAK1 recruits
CC       the adapter protein PELI1.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR: Magnesium.
CC   -!- SUBUNIT: IL-1 stimulation leads to the formation of a signaling
CC       complex which dissociates from the IL-1 receptor following the
CC       binding of PELI1. Interacts with IL1RL1. Interacts with IRAK1BP1
CC       (By similarity).
CC   -!- INTERACTION:
CC       Self; NbExp=1; IntAct=EBI-358664, EBI-358664;
CC       O43187:IRAK2; NbExp=1; IntAct=EBI-358664, EBI-447733;
CC       Q9Y616:IRAK3; NbExp=1; IntAct=EBI-358664, EBI-447690;
CC       Q99836:MYD88; NbExp=1; IntAct=EBI-358664, EBI-447677;
CC       Q9HAT8:PELI2; NbExp=2; IntAct=EBI-358664, EBI-448407;
CC       Q8N2H9:PELI3; NbExp=2; IntAct=EBI-358664, EBI-448457;
CC       Q9Y4K3:TRAF6; NbExp=3; IntAct=EBI-358664, EBI-359276;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=a;
CC         IsoId=P51617-1; Sequence=Displayed;
CC       Name=2; Synonyms=b;
CC         IsoId=P51617-2; Sequence=VSP_011851;
CC         Note=Inactive;
CC       Name=3;
CC         IsoId=P51617-3; Sequence=VSP_011849, VSP_011850, VSP_011851;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are ubiquitously
CC       expressed in all tissues examined, with isoform 1 being more
CC       strongly expressed than isoform 2.
CC   -!- PTM: Autophosphorylated or is transphosphorylated by IRAK4
CC       following recruitment to the IL-1RI. In the case of isoform 1,
CC       this is linked to ubiquitination and degradation.
CC   -!- PTM: Polyubiquitinated; after cell stimulation with IL-1-beta.
CC       Polyubiquitination occurs with polyubiquitin chains linked through
CC       'Lys-63'.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. Pelle subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L76191; AAC41949.1; -; mRNA.
DR   EMBL; U52112; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF030876; AAC08756.1; -; Genomic_DNA.
DR   EMBL; AF346607; AAK62888.1; -; mRNA.
DR   EMBL; BC054000; AAH54000.1; -; mRNA.
DR   IPI; IPI00293652; -.
DR   IPI; IPI00472717; -.
DR   IPI; IPI00940703; -.
DR   PIR; G02512; G02512.
DR   RefSeq; NP_001020413.1; -.
DR   RefSeq; NP_001020414.1; -.
DR   RefSeq; NP_001560.2; -.
DR   UniGene; Hs.522819; -.
DR   ProteinModelPortal; P51617; -.
DR   SMR; P51617; 16-124.
DR   DIP; DIP-397N; -.
DR   IntAct; P51617; 23.
DR   MINT; MINT-97088; -.
DR   STRING; P51617; -.
DR   PhosphoSite; P51617; -.
DR   PRIDE; P51617; -.
DR   Ensembl; ENST00000369980; ENSP00000358997; ENSG00000184216.
DR   GeneID; 3654; -.
DR   KEGG; hsa:3654; -.
DR   UCSC; uc004fjr.1; human.
DR   UCSC; uc004fjs.1; human.
DR   CTD; 3654; -.
DR   GeneCards; GC0XM153277; -.
DR   HGNC; HGNC:6112; IRAK1.
DR   HPA; CAB004461; -.
DR   MIM; 300283; gene.
DR   PharmGKB; PA29912; -.
DR   eggNOG; prNOG16552; -.
DR   HOGENOM; HBG283634; -.
DR   HOVERGEN; HBG052144; -.
DR   InParanoid; P51617; -.
DR   OMA; WHLTPSC; -.
DR   OrthoDB; EOG9NS5XG; -.
DR   PhylomeDB; P51617; -.
DR   BRENDA; 2.7.10.2; 247.
DR   BRENDA; 2.7.11.1; 247.
DR   Pathway_Interaction_DB; il1pathway; IL1-mediated signaling events.
DR   Pathway_Interaction_DB; p75ntrpathway; p75(NTR)-mediated signaling.
DR   Reactome; REACT_11061; Signalling by NGF.
DR   Reactome; REACT_6900; Signaling in Immune system.
DR   NextBio; 14289; -.
DR   ArrayExpress; P51617; -.
DR   Bgee; P51617; -.
DR   CleanEx; HS_IRAK1; -.
DR   Genevestigator; P51617; -.
DR   GermOnline; ENSG00000184216; Homo sapiens.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0045323; C:interleukin-1 receptor complex; NAS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004704; F:NF-kappaB-inducing kinase activity; TAS:ProtInc.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; NAS:UniProtKB.
DR   GO; GO:0016563; F:transcription activator activity; NAS:UniProtKB.
DR   GO; GO:0007250; P:activation of NF-kappaB-inducing kinase act...; IDA:UniProtKB.
DR   GO; GO:0006916; P:anti-apoptosis; EXP:Reactome.
DR   GO; GO:0070498; P:interleukin-1-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signalin...; TAS:BHF-UCL.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcript...; IMP:BHF-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcript...; IDA:BHF-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcript...; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein amino acid autophosphorylation; NAS:UniProtKB.
DR   GO; GO:0051259; P:protein oligomerization; IMP:UniProtKB.
DR   GO; GO:0001959; P:regulation of cytokine-mediated signaling p...; IMP:BHF-UCL.
DR   GO; GO:0070555; P:response to interleukin-1; IMP:BHF-UCL.
DR   GO; GO:0034134; P:toll-like receptor 2 signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0007178; P:transmembrane receptor protein serine/threo...; NAS:UniProtKB.
DR   InterPro; IPR000488; Death.
DR   InterPro; IPR011029; DEATH-like.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   Gene3D; G3DSA:1.10.533.10; DEATH_like; 1.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SUPFAM; SSF47986; DEATH_like; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Complete proteome;
KW   Direct protein sequencing; Kinase; Magnesium; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Serine/threonine-protein kinase;
KW   Transferase; Ubl conjugation.
FT   CHAIN         1    712       Interleukin-1 receptor-associated kinase
FT                                1.
FT                                /FTId=PRO_0000086030.
FT   DOMAIN      212    521       Protein kinase.
FT   NP_BIND     218    226       ATP (By similarity).
FT   ACT_SITE    340    340       Proton acceptor (By similarity).
FT   BINDING     239    239       ATP.
FT   MOD_RES     131    131       Phosphoserine.
FT   MOD_RES     371    371       Phosphoserine.
FT   MOD_RES     568    568       Phosphoserine.
FT   VAR_SEQ      45     45       F -> FGGWRRAAGGREARGLLAPTPDAPRPA (in
FT                                isoform 3).
FT                                /FTId=VSP_011849.
FT   VAR_SEQ     478    492       Missing (in isoform 3).
FT                                /FTId=VSP_011850.
FT   VAR_SEQ     513    542       Missing (in isoform 2 and isoform 3).
FT                                /FTId=VSP_011851.
FT   VARIANT     194    194       R -> H (in dbSNP:rs11465830).
FT                                /FTId=VAR_051629.
FT   VARIANT     196    196       F -> S (in dbSNP:rs1059702).
FT                                /FTId=VAR_051630.
FT   VARIANT     203    203       C -> S (in dbSNP:rs10127175).
FT                                /FTId=VAR_051631.
FT   VARIANT     398    398       T -> M (in dbSNP:rs56340948).
FT                                /FTId=VAR_040573.
FT   VARIANT     412    412       V -> M (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040574.
FT   VARIANT     421    421       Q -> H (in a breast pleomorphic lobular
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_040575.
FT   VARIANT     532    532       S -> L (in dbSNP:rs1059703).
FT                                /FTId=VAR_040576.
FT   VARIANT     619    619       G -> S (in dbSNP:rs34112487).
FT                                /FTId=VAR_040577.
FT   VARIANT     625    625       T -> M (in dbSNP:rs35638718).
FT                                /FTId=VAR_040578.
FT   VARIANT     638    638       R -> W (in dbSNP:rs56082801).
FT                                /FTId=VAR_040579.
FT   VARIANT     690    690       S -> G (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_040580.
FT   MUTAGEN     239    239       K->S: Loss of kinase activity.
SQ   SEQUENCE   712 AA;  76537 MW;  A7ADED75D3A3981D CRC64;
     MAGGPGPGEP AAPGAQHFLY EVPPWVMCRF YKVMDALEPA DWCQFAALIV RDQTELRLCE
     RSGQRTASVL WPWINRNARV ADLVHILTHL QLLRARDIIT AWHPPAPLPS PGTTAPRPSS
     IPAPAEAEAW SPRKLPSSAS TFLSPAFPGS QTHSGPELGL VPSPASLWPP PPSPAPSSTK
     PGPESSVSLL QGARPFPFCW PLCEISRGTH NFSEELKIGE GGFGCVYRAV MRNTVYAVKR
     LKENADLEWT AVKQSFLTEV EQLSRFRHPN IVDFAGYCAQ NGFYCLVYGF LPNGSLEDRL
     HCQTQACPPL SWPQRLDILL GTARAIQFLH QDSPSLIHGD IKSSNVLLDE RLTPKLGDFG
     LARFSRFAGS SPSQSSMVAR TQTVRGTLAY LPEEYIKTGR LAVDTDTFSF GVVVLETLAG
     QRAVKTHGAR TKYLKDLVEE EAEEAGVALR STQSTLQAGL AADAWAAPIA MQIYKKHLDP
     RPGPCPPELG LGLGQLACCC LHRRAKRRPP MTQVYERLEK LQAVVAGVPG HSEAASCIPP
     SPQENSYVSS TGRAHSGAAP WQPLAAPSGA SAQAAEQLQR GPNQPVESDE SLGGLSAALR
     SWHLTPSCPL DPAPLREAGC PQGDTAGESS WGSGPGSRPT AVEGLALGSS ASSSSEPPQI
     IINPARQKMV QKLALYEDGA LDSLQLLSSS SLPGLGLEQD RQGPEESDEF QS
//
